Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.67 |
| ▸ | CA9 | Q16790 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 2/20 | 0.56 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18088392 | 0.90 | CA12 (0.67) | CA12CA9ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL17174228 | 0.85 | LMNA (0.66) | CA12CA9ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL25920658 | 0.85 | ALDH1A1 (0.59) | CA12CA9ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL10212711 | 0.85 | ALDH1A1 (0.59) | CA12CA9ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL18612538 | 0.85 | TAS2R14 (0.57) | CA12CA9ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL10210777 | 0.84 | ALDH1A1 (0.58) | CA12CA9ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL812702 | 0.83 | CA12 (0.78) | CA12CA9NR1H3HTTL3MBTL1 | |
| SCHEMBL10211749 | 0.82 | ALDH1A1 (0.52) | CA12CA9ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL894820 | 0.81 | NR1H3 (0.56) | CA12CA9ALDH1A1NR1H3HTT | |
| SCHEMBL1196713 | 0.81 | NR1H3 (0.56) | CA12CA9ALDH1A1NR1H3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862714-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| EP-2838533-B1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | UNIV CASE WESTERN RESERVE (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20170066755-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8273738-B2 | Imidazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273738-B2 | Imidazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | CNR1, CNR2, ARRB1 | CA12 4475/4885CA9 3960/4885ALDH1A1 2997/4885 |
| US-20170066755-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | CA12 1677/4885CA9 1398/4885ALDH1A1 1828/4885 |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | CA12 4838/4885CA9 4447/4885ALDH1A1 2193/4885 |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | CNR1, CNR2, ARRB1 | CA12 4475/4885CA9 3960/4885ALDH1A1 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.